For someone living with frequent migraine attacks, pain medication can begin as a rescue.
The headache starts. You recognize the familiar pressure, throbbing, nausea, or sensitivity to light, and you reach for the treatment that has helped before. It works, or at least makes the attack bearable.
Then another migraine arrives.
You take the medication again.
Eventually, headaches are occurring so often that the medicine meant to provide relief is being used repeatedly throughout the month.
And somewhere along the way, something strange can happen.
The treatment used to escape headaches may become part of the cycle keeping them going.
This phenomenon is commonly called a rebound headache, although clinicians generally use the term medication-overuse headache. It is particularly common among people who already experience frequent or chronic migraine.
Now research suggests that a preventive migraine drug called atogepant may help people caught in this frustrating cycle—reducing not only migraine days, but also the number of days they need acute pain medication. The findings have since become even more relevant: updated 2026 migraine-prevention guidelines specifically list atogepant among preventive treatments with evidence in people who have medication overuse or medication-overuse headache. American Academy of Neurology
When Headache Medicine Starts Creating More Headache
The idea sounds almost impossible at first.
If a medicine reduces headaches, how could taking it lead to more headaches?
The problem isn’t usually an occasional dose.
Medication-overuse headache develops in people who already have an underlying headache disorder—most commonly migraine—and use acute headache treatments very frequently.
As the pattern continues, the nervous system may become increasingly sensitized.
The person begins experiencing headaches on more days.
More headaches lead to more medication.
More medication can reinforce the cycle.
Eventually, it becomes difficult to tell where the original migraine ends and the medication-overuse headache begins.
It Isn’t About Addiction
This distinction matters.
Someone who repeatedly takes migraine medication isn’t necessarily addicted to it.
Imagine experiencing severe migraine pain several times every week. You have work to do, children to care for, appointments to attend, and a life that doesn’t conveniently stop whenever your nervous system decides to produce an attack.
Of course you reach for something that provides relief.
The problem is that certain acute headache medications, when used too frequently, can contribute to medication overuse and potentially to additional headaches.
Current U.S. neurology guidance defines medication overuse according to how frequently acute treatments are used: generally more than nine days per month for prescription migraine pain-relieving drugs or more than fourteen days per month for nonspecific pain medicines. The precise threshold depends on the medication involved. American Academy of Neurology
Chronic Migraine Creates the Perfect Trap
Chronic migraine is generally characterized by headaches occurring on at least 15 days per month, with migraine features present on a substantial portion of those days.
Think about what that means practically.
Half the month—or more—can contain headache.
If someone treats most of those days with acute medication, medication use can quickly become frequent enough to create another problem.
The person isn’t taking medication irresponsibly.
They’re responding logically to repeated pain.
That’s what makes medication-overuse headache such a difficult clinical problem.
Telling someone simply to “stop taking painkillers” can sound straightforward from the outside.
It’s considerably less straightforward when the alternative is spending the day with a disabling migraine.
Prevention Changes the Question
Acute migraine medication asks:
How do we stop this attack?
Preventive medication asks something different:
How do we make the attacks happen less often in the first place?
That distinction may be especially valuable for people with medication overuse.
If preventive treatment reduces the number of migraines someone experiences, they naturally have fewer occasions when they need rescue medication.
Instead of repeatedly treating the consequences, prevention attempts to reduce how often the problem begins.
Atogepant was developed for precisely this preventive role.
What Is Atogepant?
Atogepant belongs to a newer class of migraine medications called gepants.
These drugs target a signaling molecule known as calcitonin gene-related peptide, or CGRP.
CGRP has become one of the most important targets in modern migraine research.
During migraine attacks, CGRP signaling is involved in pain pathways within the nervous system. Researchers discovered that interfering with this system could prevent or treat migraine in many people.
That led to the development of several CGRP-targeting therapies.
Some are monoclonal antibodies given by injection or infusion.
Others—including atogepant—are small-molecule medications taken orally.
Atogepant is used as a preventive treatment rather than simply waiting for an attack and responding after it begins.
Researchers Asked an Important Question
Clinical trials had already demonstrated that atogepant could reduce migraine frequency.
But researchers wanted to know whether it would also work in a particularly difficult group:
people with chronic migraine who were already overusing acute headache medication.
These patients matter because they’re often caught in the most stubborn version of the migraine cycle.
More headaches.
More rescue medication.
More risk of rebound headache.
Then still more medication.
If preventive treatment could reduce attacks in this population, it might help interrupt several parts of the cycle simultaneously.
The Results Were Encouraging
In the study highlighted by the American Academy of Neurology, people with chronic migraine and acute medication overuse who received atogepant experienced fewer monthly migraine days and fewer headache days. Importantly, they also had fewer days on which they needed acute headache medication. American Academy of Neurology
That last finding may be especially meaningful.
Reducing migraine frequency is obviously important.
But for someone with medication overuse, reducing reliance on rescue treatment addresses another part of the problem.
If migraines become less frequent, the need for acute medication may fall.
And if acute medication use falls below overuse levels, the rebound component of the headache pattern may begin to loosen its grip.
The Cycle Can Potentially Run in Reverse
Medication-overuse headache can feel like a loop:
migraine → medication → another headache → more medication → more headaches.
Effective prevention creates the possibility of reversing that pattern:
fewer migraines → less rescue medication → less medication overuse → fewer rebound headaches.
Of course, real life isn’t always that neat.
People differ.
Some require structured withdrawal from the overused medication.
Some may temporarily feel worse when reducing it.
Others may have multiple headache triggers or additional medical conditions.
But preventive therapy gives clinicians another way to approach the problem rather than relying exclusively on withdrawal.
Do You Have to Stop the Overused Medicine First?
Historically, withdrawing the medication being overused has been a central part of treating medication-overuse headache.
That approach still matters.
But the timing of prevention is evolving.
Current expert guidance recommends addressing medication overuse, but it also emphasizes that doing so should not unnecessarily delay effective migraine prevention. The 2026 American Academy of Neurology/American Headache Society guideline recommends offering preventive treatment to people with migraine who meet criteria for medication overuse or medication-overuse headache. American Academy of Neurology
That represents an important shift in thinking.
Rather than saying:
“First stop everything, suffer through the transition, and then we’ll consider prevention,”
treatment can increasingly address the underlying migraine disorder at the same time.
Atogepant Isn’t the Only Preventive Option
The broader story isn’t really about one drug.
Several preventive treatments now have evidence in people with medication overuse.
The 2026 U.S. guideline specifically identifies CGRP monoclonal antibodies, atogepant, onabotulinumtoxinA—commonly known as Botox—and topiramate as options with evidence supporting their use in this population. American Academy of Neurology
That gives clinicians more possibilities for matching treatment to the individual.
Someone’s previous treatments matter.
Other medical conditions matter.
Side effects matter.
Cost and insurance coverage can matter.
Personal preference matters.
Migraine prevention is becoming less about finding the universal drug and more about finding the appropriate treatment for a particular person.
Newer Research Supports the Same General Direction
The evidence has continued developing.
A 2026 real-world study involving 47 people with chronic migraine and medication-overuse headache examined anti-CGRP preventive treatment alongside individualized reduction of overused medication. At six months, 85.1% had achieved at least a 50% reduction in monthly migraine days; by 12 months, 78.7% had achieved reductions greater than 75%. Because this was a small, single-center observational dataset rather than a randomized trial, the percentages shouldn’t be assumed to apply to everyone, but the results support continued investigation of prevention combined with addressing medication overuse. Frontiers
The important theme is becoming increasingly consistent:
Treating the migraine itself can be an important part of escaping medication overuse.
Why CGRP Became Such an Important Target
Migraine was once treated largely as a vascular headache.
Scientists now understand it as a much more complex neurological disorder.
CGRP participates in pain transmission and other processes involved in migraine attacks.
Blocking the CGRP pathway doesn’t simply numb pain in the way a traditional analgesic might.
It targets part of the biological machinery involved in migraine.
That difference is important.
Instead of repeatedly suppressing individual attacks after they’ve started, preventive CGRP-targeting treatments attempt to reduce the likelihood or frequency of attacks.
For someone experiencing headaches on half the days of every month, preventing even several attacks can translate into a substantial amount of life returned.
Count Medication Days, Not Just Headaches
People with frequent migraine often know approximately how many headaches they experience.
Fewer know exactly how many days each month they use acute medication.
That number can be extremely useful.
A headache diary can record:
when the headache began,
whether it had migraine features,
which medication was taken,
whether another dose was needed,
and whether the treatment worked.
Patterns that feel impossible to recognize during a difficult month can become obvious when written down.
“I only take something when I really need it” can sometimes turn out to mean fifteen or twenty treatment days every month.
That’s valuable information—not a reason for guilt.
A Headache Diary Can Reveal the Cycle
Imagine recording every headache and medication day for three months.
Month one: 17 headache days and 14 treatment days.
Month two: 19 headache days and 16 treatment days.
Month three: 18 headache days and 15 treatment days.
Suddenly, what felt random has structure.
That record gives a clinician much more useful information than simply saying, “I get headaches all the time.”
It can also reveal whether preventive treatment is working.
Perhaps the first month changes little.
Then 18 headache days become 13.
Thirteen become nine.
Acute medication days decline too.
Those changes can be meaningful even if migraine hasn’t disappeared completely.
Success Doesn’t Have to Mean Zero Migraines
This is an important psychological shift.
Someone beginning preventive treatment understandably hopes the headaches vanish forever.
Sometimes improvement can be dramatic.
But migraine prevention is often judged by reduction rather than complete elimination.
Fewer migraine days.
Less severe attacks.
Shorter attacks.
Less rescue medication.
Fewer missed days of work.
More predictable plans.
Better sleep.
More days when migraine isn’t determining what you can and cannot do.
A person going from fifteen migraine days each month to seven still has migraine.
But they’ve also regained roughly eight days.
Over a year, that’s close to one hundred days.
Numbers become very different when translated back into life.
Rebound Headaches Are Treatable
People caught in medication overuse can become understandably discouraged.
They take medicine because they hurt.
Then they’re told the medicine may be contributing to the pain.
Stopping it can initially feel impossible.
Continuing it feels equally impossible.
Preventive therapies offer another route into that cycle.
Rather than focusing entirely on taking away the treatment someone relies on, clinicians can simultaneously work on reducing the number of attacks creating the need for that treatment.
That approach is both biologically logical and increasingly supported by evidence.
Don’t Suddenly Stop Certain Medications on Your Own
One caution matters.
Not every medication should be abruptly discontinued without guidance.
The safest strategy depends on which drug is being overused, how frequently it is taken, and the person’s other medical conditions.
Some medications can be reduced relatively straightforwardly.
Others may require a structured taper or closer supervision.
That’s why suspected medication-overuse headache is worth discussing with a clinician familiar with headache treatment rather than attempting an improvised “detox.”
The objective isn’t simply to endure withdrawal.
It’s to build a sustainable plan that reduces both migraine frequency and dependence on acute treatment.
The Goal Is to Need Rescue Less Often
There is something almost paradoxical about the best rescue medicine.
Ideally, you eventually need less of it.
That is where prevention changes the experience of migraine.
Instead of waking up wondering whether today will become another medication day, the number of attacks begins to fall.
Instead of carrying rescue medication everywhere because headaches feel inevitable, there may be increasingly long stretches when it isn’t needed.
And for someone experiencing medication-overuse headache, that can break a cycle that once seemed impossible to escape.
The emerging evidence around atogepant and other preventive therapies doesn’t mean rebound headache has suddenly become simple to treat.
But it does change the conversation.
The person isn’t merely told to stop taking the medication that gets them through the day.
There is another question to ask:
What if we can prevent enough migraines that you don’t need to reach for it so often in the first place?
For people trapped between frequent migraine and frequent medication use, that may be one of the most important questions modern headache medicine is beginning to answer.
For more on how your body’s systems are interconnected, check out how better blood sugar days may also be better life days for people with diabetes, or learn how coffee may be talking to your brain through your gut. You might also be interested in why your brain may be aging faster than you are – and MRI scans are revealing why.
